{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:04:18Z","timestamp":1792242258970,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40744-024-00677-y","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T15:04:30Z","timestamp":1720019070000},"page":"1135-1164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-7277","authenticated-orcid":false,"given":"Grace C.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8993-0313","authenticated-orcid":false,"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Cadatal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Germino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Yndestad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-1668","authenticated-orcid":false,"given":"Cassandra D.","family":"Kinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"677_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/rheumatology\/39.2.122","volume":"39","author":"DL Scott","year":"2000","unstructured":"Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford). 2000;39:122\u201332.","journal-title":"Rheumatology (Oxford)"},{"key":"677_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","volume":"70","author":"V Strand","year":"2010","unstructured":"Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs. 2010;70:121\u201345.","journal-title":"Drugs"},{"key":"677_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44:123\u201330.","journal-title":"Semin Arthritis Rheum"},{"key":"677_CR4","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1093\/rheumatology\/ket166","volume":"52","author":"W Kievit","year":"2013","unstructured":"Kievit W, Fransen J, de Waal Malefijt MC, den Broeder AA, van Riel PLCM. Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatology (Oxford). 2013;52:1500\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"677_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.amjmed.2013.09.002","volume":"126","author":"JD Greenberg","year":"2013","unstructured":"Greenberg JD, Spruill TM, Shan Y, et al. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med. 2013;126:1089\u201398.","journal-title":"Am J Med"},{"key":"677_CR6","first-page":"1475","volume":"34","author":"B Bruce","year":"2007","unstructured":"Bruce B, Fries JF, Murtagh KN. Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol. 2007;34:1475\u20139.","journal-title":"J Rheumatol"},{"key":"677_CR7","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/rheumatology\/keg354","volume":"42","author":"PS Helliwell","year":"2003","unstructured":"Helliwell PS, Ibrahim G. Ethnic differences in responses to disease modifying drugs. Rheumatology (Oxford). 2003;42:1197\u2013201.","journal-title":"Rheumatology (Oxford)"},{"key":"677_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/healthcare10040603","volume":"10","author":"MR Cullen","year":"2022","unstructured":"Cullen MR, Lemeshow AR, Russo LJ, Barnes DM, Ababio Y, Habtezion A. Disease-specific health disparities: a targeted review focusing on race and ethnicity. Healthcare (Basel). 2022;10:603.","journal-title":"Healthcare (Basel)"},{"key":"677_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/art.11000","volume":"49","author":"I Del Rincon","year":"2003","unstructured":"Del Rincon I, Battafarano DF, Arroyo RA, Murphy FT, Fischbach M, Escalante A. Ethnic variation in the clinical manifestations of rheumatoid arthritis: role of HLA-DRB1 alleles. Arthritis Rheum. 2003;49:200\u20138.","journal-title":"Arthritis Rheum"},{"key":"677_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1089\/jwh.2020.8868","volume":"30","author":"JJ Chinn","year":"2021","unstructured":"Chinn JJ, Martin IK, Redmond N. Health equity among black women in the United States. J Womens Health (Larchmt). 2021;30:212\u20139.","journal-title":"J Womens Health (Larchmt)"},{"key":"677_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1377\/hlthaff.24.2.325","volume":"24","author":"DR Williams","year":"2005","unstructured":"Williams DR, Jackson PB. Social sources of racial disparities in health. Health Aff (Millwood). 2005;24:325\u201334.","journal-title":"Health Aff (Millwood)"},{"key":"677_CR12","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/MLR.0b013e31818af829","volume":"47","author":"F Constantinescu","year":"2009","unstructured":"Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care. 2009;47:350\u20135.","journal-title":"Med Care"},{"key":"677_CR13","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.semarthrit.2020.07.008","volume":"50","author":"I Navarro-Mill\u00e1n","year":"2020","unstructured":"Navarro-Mill\u00e1n I, Rajan M, Lui GE, et al. Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis. Semin Arthritis Rheum. 2020;50:988\u201395.","journal-title":"Semin Arthritis Rheum"},{"key":"677_CR14","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1756-185X.14185","volume":"24","author":"A Chopra","year":"2021","unstructured":"Chopra A, Lin H-Y, Navarra SV, et al. Rheumatoid arthritis management in the APLAR region: perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases. Int J Rheum Dis. 2021;24:1106\u201311.","journal-title":"Int J Rheum Dis"},{"key":"677_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.reuma.2012.09.001","volume":"9","author":"R Burgos-Vargas","year":"2013","unstructured":"Burgos-Vargas R, Catoggio LJ, Galarza-Maldonado C, Ostojich K, Cardiel MH. Current therapies in rheumatoid arthritis: a Latin American perspective. Reumatol Clin. 2013;9:106\u201312.","journal-title":"Reumatol Clin"},{"key":"677_CR16","volume":"13","author":"WH Zahir Hussain","year":"2021","unstructured":"Zahir Hussain WH, Jubber A, Moorthy A. Are there any ethnic differences in the response to baricitinib for the treatment of rheumatoid arthritis? Cureus. 2021;13: e20024.","journal-title":"Cureus"},{"key":"677_CR17","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60:1895\u2013905.","journal-title":"Arthritis Rheum"},{"key":"677_CR18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"JM Kremer","year":"2012","unstructured":"Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970\u201381.","journal-title":"Arthritis Rheum"},{"key":"677_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/art.33383","volume":"64","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617\u201329.","journal-title":"Arthritis Rheum"},{"key":"677_CR20","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/acr.20494","volume":"63","author":"Y Tanaka","year":"2011","unstructured":"Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63:1150\u20138.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"677_CR21","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14397595.2014.995875","volume":"25","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25:514\u201321.","journal-title":"Mod Rheumatol"},{"key":"677_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451\u201360.","journal-title":"Lancet"},{"key":"677_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559\u201370.","journal-title":"Arthritis Rheum"},{"key":"677_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med"},{"key":"677_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253\u201361.","journal-title":"Ann Intern Med"},{"key":"677_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508\u201319.","journal-title":"N Engl J Med"},{"key":"677_CR27","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377\u201386.","journal-title":"N Engl J Med"},{"key":"677_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457\u201368.","journal-title":"Lancet"},{"key":"677_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.reuma.2016.04.010","volume":"13","author":"SC Radominski","year":"2017","unstructured":"Radominski SC, Cardiel MH, Citera G, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: pooled efficacy and safety analyses of Phase 3 and long-term extension studies. Reumatol Clin. 2017;13:201\u20139.","journal-title":"Reumatol Clin"},{"key":"677_CR30","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/1756-185X.13516","volume":"22","author":"EB Lee","year":"2019","unstructured":"Lee EB, Yamanaka H, Liu Y, et al. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: post-hoc analyses of pooled clinical study data. Int J Rheum Dis. 2019;22:1094\u2013106.","journal-title":"Int J Rheum Dis"},{"key":"677_CR31","first-page":"2400","volume":"34","author":"ME Suarez-Almazor","year":"2007","unstructured":"Suarez-Almazor ME, Berrios-Rivera JP, Cox V, Janssen NM, Marcus DM, Sessoms S. Initiation of disease-modifying antirheumatic drug therapy in minority and disadvantaged patients with rheumatoid arthritis. J Rheumatol. 2007;34:2400\u20137.","journal-title":"J Rheumatol"},{"key":"677_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/art.24338","volume":"61","author":"F Constantinescu","year":"2009","unstructured":"Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum. 2009;61:413\u20138.","journal-title":"Arthritis Rheum"},{"key":"677_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/art.1790110203","volume":"11","author":"MS Jordan","year":"1998","unstructured":"Jordan MS, Lumley MA, Leisen JC. The relationships of cognitive coping and pain control beliefs to pain and adjustment among African-American and Caucasian women with rheumatoid arthritis. Arthritis Care Res. 1998;11:80\u20138.","journal-title":"Arthritis Care Res"},{"key":"677_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/BOR.0000000000000782","volume":"33","author":"K Yip","year":"2021","unstructured":"Yip K, Navarro-Mill\u00e1n I. Racial, ethnic, and healthcare disparities in rheumatoid arthritis. Curr Opin Rheumatol. 2021;33:117\u201321.","journal-title":"Curr Opin Rheumatol"},{"key":"677_CR35","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/acr.21680","volume":"64","author":"L Massardo","year":"2012","unstructured":"Massardo L, Pons-Estel BA, Wojdyla D, et al. Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline. Arthritis Care Res (Hoboken). 2012;64:1135\u201343.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"677_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3899\/jrheum.131382","volume":"42","author":"G Yang","year":"2015","unstructured":"Yang G, Bykerk VP, Boire G, et al. Does socioeconomic status affect outcomes in early inflammatory arthritis? Data from a Canadian multisite suspected rheumatoid arthritis inception cohort. J Rheumatol. 2015;42:46\u201354.","journal-title":"J Rheumatol"},{"key":"677_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s13075-015-0836-6","volume":"17","author":"X Jiang","year":"2015","unstructured":"Jiang X, Sandberg MEC, Saevarsdottir S, Klareskog L, Alfredsson L, Bengtsson C. Higher education is associated with a better rheumatoid arthritis outcome concerning for pain and function but not disease activity: results from the EIRA cohort and Swedish rheumatology register. Arthritis Res Ther. 2015;17:317.","journal-title":"Arthritis Res Ther"},{"key":"677_CR38","unstructured":"European Medicines Agency. Xeljanz (tofacitinib citrate): summary of product characteristics. 2021. https:\/\/www.medicines.org.uk\/emc\/medicine\/33167. Accessed 20 Nov 2023."},{"key":"677_CR39","unstructured":"US Food and Drug Administration. XELJANZ\u00ae (tofacitinib) highlights of prescribing information. 2018. http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=959. Accessed 20 Nov 2023."},{"key":"677_CR40","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3899\/jrheum.190008","volume":"47","author":"K Bechman","year":"2020","unstructured":"Bechman K, Yates M, Norton S, Cope AP, Galloway JB. Placebo response in rheumatoid arthritis clinical trials. J Rheumatol. 2020;47:28\u201334.","journal-title":"J Rheumatol"},{"key":"677_CR41","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848\u201358.","journal-title":"Ann Rheum Dis"},{"key":"677_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48\u201355.","journal-title":"Ann Rheum Dis"},{"key":"677_CR43","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","volume":"76","author":"SB Cohen","year":"2017","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76:1253\u201362.","journal-title":"Ann Rheum Dis"},{"key":"677_CR44","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1133\u20138.","journal-title":"Ann Rheum Dis"},{"key":"677_CR45","unstructured":"Pfizer Canada Inc. Xeljanz (Product Monograph). 2023. https:\/\/pdf.hres.ca\/dpd_pm\/00070739.PDF. Accessed 20 Nov 2023."},{"key":"677_CR46","unstructured":"Rastogi S, Johnson T, Hoeffel E, Drewery (Jr) M. The Black Population: 2010. 2011. https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2011\/dec\/c2010br-06.pdf. Accessed 20 Nov 2023."},{"key":"677_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106421","volume":"106","author":"M Rottas","year":"2021","unstructured":"Rottas M, Thadeio P, Simons R, et al. Demographic diversity of participants in Pfizer sponsored clinical trials in the United States. Contemp Clin Trials. 2021;106: 106421.","journal-title":"Contemp Clin Trials"},{"key":"677_CR48","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/jama.2020.11244","volume":"324","author":"MC Jaklevic","year":"2020","unstructured":"Jaklevic MC. Researchers strive to recruit hard-hit minorities into COVID-19 vaccine trials. JAMA. 2020;324:826\u20138.","journal-title":"JAMA"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00677-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00677-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00677-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T19:23:06Z","timestamp":1742066586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00677-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["677"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00677-y","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Grace C. Wright has acted as a consultant for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Exagen, GSK, Janssen, Novartis, Pfizer Inc, Sanofi, Scipher Medicine, and UCB; is an officer\/board member for the Association of Women in Rheumatology; and is a member of the speakers\u2019 bureau for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli\u00a0Lilly, Novartis, Sanofi, and UCB. Eduardo Mysler has received grant\/research support from Eli Lilly, Janssen, Pfizer\u00a0Inc, and Roche; and is a member of the speakers\u2019 bureau for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer Inc, Roche, and Sanofi. Kenneth Kwok, Mary Jane Cadatal, and Arne Yndestad are employees and stockholders of Pfizer Inc. Rebecca Germino and Cassandra D. Kinch were employees and stockholders of Pfizer Inc at the time of this work. Alexis Ogdie has acted as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, Eli Lilly, Gilead, GSK, Janssen, Novartis, Pfizer Inc, and UCB; and has received grant\/research support from AbbVie, Amgen, Janssen, Novartis, and Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Each study was conducted in accordance with the Declaration of Helsinki, International Council for Harmonisation Guidelines for Good Clinical Practice and local country regulations, and approved by the Institutional Review Board and Independent Ethics Committee at each center. Patients provided written informed consent. No further ethical approval was required for this post hoc analysis in accordance with the policies of our institutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}